BRUKER CORP (BRKR)
Sector: Health Care
2026 Annual Meeting Analysis
BRUKER CORP · Meeting: May 21, 2026
Directors FOR
2
Directors AGAINST
1
Say on Pay
FOR
Auditor
FOR
Director Elections
Election of Three Class II Directors: John J. (Jack) Phillips, Hermann F. Requardt, Ph.D., and Laura A. Francis
Against Analysis
Dr. Requardt has served since 2015, giving him full overlap with the 3-year underperformance period. Bruker's 3-year stock return of -51.5% trails the company's own compensation peer group median by 41.2 percentage points, which exceeds the 20-percentage-point trigger threshold that applies when absolute returns are negative. The 5-year check does not provide relief — Bruker's 5-year return of -43.5% trails the peer median by 45.6 percentage points, also exceeding the 20-point threshold, confirming this is sustained rather than transient underperformance.
For Analysis
Mr. Phillips joined the board in early 2026 and is exempt from the stock performance trigger under the policy's 24-month new-director exemption; he brings strong relevant industry experience in diagnostics and medical devices.
Ms. Francis joined the board in February 2025 and has been a director for approximately 14 months as of the meeting date, which is within the 24-month new-director exemption window, so she is not subject to the stock performance trigger; she also brings strong financial and life science expertise relevant to the company.
Of the three Class II nominees, Mr. Phillips and Ms. Francis both qualify for the 24-month new-director exemption from the stock performance trigger and receive FOR votes. Dr. Requardt, a director since 2015, is subject to the full trigger: Bruker's 3-year return of -51.5% lags the company-disclosed peer group median by 41.2 percentage points — well above the 20-point threshold — and the 5-year picture is equally weak (-45.6pp gap), so the AGAINST vote is not downgraded.
Say on Pay
✓ FORCEO
Frank H. Laukien, Ph.D.
Total Comp
$4,706,388
Prior Support
95%%
CEO total compensation of approximately $4.7 million is modest for a company of Bruker's size and market cap, and is unlikely to be above benchmark for a CEO in this sector and market cap band. The compensation program responded appropriately to poor 2025 financial results — cash bonus payouts ranged from only 32% to 53% of target across the named executive officers, salaries were held flat at the CEO's own recommendation, and the equity awards are time-based with four-year vesting rather than immediately earned regardless of results. The prior say-on-pay vote received 95% support, the company has a meaningful clawback policy, and the pay structure is predominantly variable (82% at-risk for the CEO), all of which pass the policy screens.
Auditor Ratification
✓ FORAuditor
PricewaterhouseCoopers LLP
Tenure
N/A
Audit Fees
$11,484,362
Non-Audit Fees
$2,771,838
Non-audit fees (tax fees of $2,762,715 plus audit-related fees of $7,123 plus other fees of $2,000, totaling approximately $2,771,838) represent about 24% of audit fees of $11,484,362, well below the 50% threshold that would raise independence concerns; auditor tenure is not disclosed in the filing so the tenure trigger cannot fire; PwC is a Big 4 firm appropriate for a company of Bruker's size and complexity.
Overall Assessment
The 2026 Bruker annual meeting presents three proposals: a vote FOR ratifying PwC as auditor (non-audit fees well within limits), a vote FOR on executive pay (modest CEO compensation with bonus payouts reflecting weak 2025 performance), and a split director vote — FOR two new directors (Phillips and Francis, both exempt as recent appointees) but AGAINST long-tenured director Dr. Requardt given Bruker's severe and sustained stock underperformance relative to its own disclosed peer group over both three and five years. No stockholder proposals appear on the ballot.
Compensation Peer Group
15 companies disclosed in 2026 proxy filing